It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
DNA methylation is considered a stable epigenetic mark, yet methylation patterns can vary during differentiation and in diseases such as cancer. Local levels of DNA methylation result from opposing enzymatic activities, the rates of which remain largely unknown. Here we developed a theoretical and experimental framework enabling us to infer methylation and demethylation rates at 860,404 CpGs in mouse embryonic stem cells. We find that enzymatic rates can vary as much as two orders of magnitude between CpGs with identical steady-state DNA methylation. Unexpectedly, de novo and maintenance methylation activity is reduced at transcription factor binding sites, while methylation turnover is elevated in transcribed gene bodies. Furthermore, we show that TET activity contributes substantially more than passive demethylation to establishing low methylation levels at distal enhancers. Taken together, our work unveils a genome-scale map of methylation kinetics, revealing highly variable and context-specific activity for the DNA methylation machinery.
Local activity of the DNA methylation machinery remains poorly understood. Here, the authors present a theoretical and experimental framework to infer methylation and demethylation rates at genome scale in mouse embryonic stem cells, finding that maintenance methylation activity is reduced at transcription factor binding sites, while methylation turnover is elevated in transcribed gene bodies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (GRID:grid.482245.d) (ISNI:0000 0001 2110 3787)
2 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (GRID:grid.482245.d) (ISNI:0000 0001 2110 3787); Swiss Institute of Bioinformatics, Basel, Switzerland (GRID:grid.419765.8) (ISNI:0000 0001 2223 3006)
3 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (GRID:grid.482245.d) (ISNI:0000 0001 2110 3787); Department of Biochemistry, University of Oxford, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
4 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (GRID:grid.482245.d) (ISNI:0000 0001 2110 3787); Novartis Institutes for Biomedical Research, Basel, Switzerland (GRID:grid.419481.1) (ISNI:0000 0001 1515 9979)
5 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (GRID:grid.482245.d) (ISNI:0000 0001 2110 3787); University of Basel, Faculty of Sciences, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642)
6 Leopold-Franzens-University Innsbruck & CMBI, Innsbruck, Austria (GRID:grid.5771.4) (ISNI:0000 0001 2151 8122)
7 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (GRID:grid.482245.d) (ISNI:0000 0001 2110 3787); EMBL Heidelberg, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X)